Edwin DeJesus MD FACP, FIDSA

Infectious Disease•Orlando, FL

HIV/AIDS Medicine, STD Medicine

Medical Director - Orlando Immunology Center and Assistant Professor - UCF College of Medicine

Join to View Full Profile

1707 N Mills AveOrlando, FL 32803
Phone+1 407-647-3960
Fax+1 407-413-5775

Education & Training

Drexel University College of Medicine/Hahnemann University HospitalFellowship, Infectious Disease, 1991 - 1993
Drexel University College of Medicine/Hahnemann University HospitalResidency, Internal Medicine, 1988 - 1991
University of Puerto Rico School of MedicineClass of 1988

Certifications & Licensure

FL State Medical License 1993 - 2026
PA State Medical License 1990 - 1994

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Centricity Practice Solution EMR, GE Healthcare, 2014

Clinical Trials

Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation Start of enrollment: 2006 Mar 31
Completed
Phase 1, Phase 2
Evolution of L74V or K65R Mutations in VIremic Subjects on Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) (EVITA) Start of enrollment: 2006 Apr 01
Completed
Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A Start of enrollment: 2006 Sep 01
Completed
Phase 2
HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network Start of enrollment: 2011 Nov 01
Completed
Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV Start of enrollment: 2015 Aug 01
Completed
Phase 3
Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1 Start of enrollment: 2016 Mar 01
Completed
Phase 3
A Clinical Trial of STP0404 in Adults with HIV-1 Infection Start of enrollment: 2023 May 23
RECRUITING
PHASE2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Lenacapavir Plus Two Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab.
Joseph J Eron, Paul P Cook, Megha L Mehrotra, Hailin Huang, Marina Caskey
The Journal of Infectious Diseases. 2025-04-03
Leronlimab Treatment for Multidrug-Resistant HIV-1 (OPTIMIZE): a Randomized, Double-Blind, Placebo-Controlled Trial.
Joseph C Gathe, Edwin Dejesus, Moti N Ramgopal, Charlotte-Paige Rolle, Otto O Yang
Journal of Acquired Immune Deficiency Syndromes. 2025-02-20
Bictegravir/emtricitabine/tenofovir alafenamide in adults with HIV-1 and end-stage kidney disease on chronic haemodialysis.
Joseph J Eron, Moti Ramgopal, Olayemi Osiyemi, Mehri Mckellar, Jihad Slim
HIV Medicine. 2025-02-01

Journal Articles

Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection
Michael Kozal, Edwin Dejesus, Cyril Llamoso, The New England Journal of Medicine

Press Mentions

Treatment-Related Early Discontinuations and Adverse Events Among Newly Diagnosed People Living with HIV Initiating Integrase Inhibitors in a Real-World SettingFebruary 1st, 2023
Orlando Trial for New Types of COVID-19 Monoclonal Antibody Treatment Seeks ParticipantsDecember 15th, 2021
'Elite Neutralizing' Antibody Demonstrates Long-Term Viral Suppression in Persons Living with HIV in Phase 1 TrialOctober 14th, 2021
Join now to see all